EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor
World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration